Answers are grounded in this paper and cite their sources.
BACKGROUND: Health-related quality of life (HRQoL) contributes to the value of immune checkpoint inhibitors (ICIs), but assessment and reporting remain heterogeneous. METHODS: This PRISMA 2020-compliant systematic review and meta-analysis was registered in PROSPERO (CRD420261330878). PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched for RCTs of adults with solid tumors comparing ICI-based regimens with non-ICI controls and reporting global HRQoL with the EORTC QLQ-C30 GHS/QoL scale or EQ-5D-3L/5L visual analogue scale (VAS). Pooling required a visit-specific adjusted between-group estimate with a 95% confidence interval (CI) or standard error. Random-effects models (restricted maximum likelihood, Hartung-Knapp adjustment) were used. Clinical relevance was assessed using instrument-specific MID benchmarks. RESULTS: Eighty-two RCTs were included: 42 in the quantitative and 40 in the narrative synthesis, 40 reported EORTC QLQ-C30 GHS/QoL, 10 EQ-5D-3L VAS, and 14 EQ-5D-5L VAS. All pooled trials evaluated anti-PD-1-based regimens. The pooled LSMD for EORTC QLQ-C30 GHS/QoL was 1.78 points (95% CI 0.71-2.86; p = 0.002; I2 =71.9%). Neither EQ-5D VAS differ significantly. Most trial-level estimates were below the MID, and no trial showed clinically meaningful deterioration. Favorable estimates were concentrated in open-label active-control, advanced/metastatic and lung cancer trials. CONCLUSION: Anti-PD-1-based therapy results in no clinically important difference in global HRQoL compared with non-ICI controls: the small average advantage is below the MID and concentrated in open-label active-control trials. Interpretation is shaped by trial design, comparator, setting, assessment timing, and incomplete PRO reporting. Standardized PRO reporting is needed across cancer settings and ICI classes.
No takes yet. Share an insight, caveat, or question.
Ciccimarra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: